Özgür MEHTAP, Abdullah HACIHANEFİOĞLU, Emel GÖNÜLLÜ, Hakan KESKİ

Yaygın ölümcül trombozlarla seyreden idiyopatik hipereozinofilik sendrom

Tekrarlayan ve yaygın trombozların altında sistemik hastalıklar yatabilir. Bunlardan biri de idiyopatik hipereozinofilik sendromdur. Altta yatan ikincil bir nedenin bulunamadığı eozinofiliyle birlikte hedef organ hasarı bulgusunun da olduğu bir durumdur. Etkilenen hedef organlar sıklıkla kalp, akciğer, merkezi ve periferik sinir sistemi ve cilttir. Hipereozinofilik hastalıklar, kanda ve dokularda eozinofil sayısının artmasıyla ilişkilidir. Eozinofiliyi etkili bir şekilde tedavi edebilmek için doğru tanı çok önemlidir. Bu yazıda, trombotik komplikasyonlar yüzünden kaybedilen idiyopatik hipereozinofilik sendromlu 38 yaşında bir erkek hasta sunuldu

Idiopathic hypereosinophilic syndrome with disseminated fatal thrombosis: a case report

Systemic diseases may be present in the underlying recurrent and disseminated thromboses. One of them is idiopathic hypereosinophilic syndrome. It is a condition which is associated with the presence of eosinophilia without a secondary underlying cause and also with an evidence of end-organ damage. Affected end organs are most frequently the heart, lungs, the central and peripheral nervous system, and the skin. Hypereosinophilic disorders are associated with the increased counts of eosinophils in the blood and tissues. Correct diagnosis is of utmost importance for effective management of eosinophilia. Herein, we present a 38-year-old male patient with idiopathic hypereosinophilic syndrome who died due to thrombotic complications

PDF

___

Kapısız NS, Kapısız HF, Ceylan D, Yücel E. Üst ekstremite derin ven trombozlu hastaların değerlendirilmesi. Turk Gogus Kalp Dama 2007;15:281-5.
Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 2010;85:158-64.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
Bain BJ, Gilliland DG, Horny HP, Vardiman JW. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In: Swerdlow SH, editor. WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2008. p. 68-73.
Bain BJ, Gilliland DG, Vardiman JW ,Horny HP. Chronic eosinophilic leukemia, not otherwise specified. In: Swerdlow SH, editor. WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2008. p. 51-3.
Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, Majewski M, Kyrcz-Krzemien S. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica 2009;94:1236-41.
Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am 2007;27:357-75.
Klion AD. How I treat hypereosinophilic syndromes. Blood 2009;114:3736-41.
Narayan S, Ezughah F, Standen GR, Pawade J, Kennedy CT. Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis. Br J Dermatol 2003;148:817-20.
Sakuta R, Tomita Y, Ohashi M, Nagai T, Murakami N. Idiopathic hypereosinophilic syndrome complicated by central sinovenous thrombosis. Brain Dev 2007;29:182-4.